Abstract:Abstract Background Preeclampsia is a severe complication of pregnancy that can impose a significant economic burden and pose a serious threat to the health of both mothers and infants. Currently, there are no effective treatment methods for established preeclampsia other than delivering the placenta. Methods We performed differential analysis and weighted correlation network analysis (WGCNA) on RNA-seq datasets to identify highly associated blood system biomarkers in preeclampsia. The expression levels and potential predictive value of these biomarkers were validated through ELISA experiments. Subsequently, multiple bioinformatics analyses were conducted to predict the biological activities and gene mappings of the selected genes. The changes in the proportions of blood immune cells and abnormal cell-cell communication in the pathogenesis of preeclampsia were explored through analysis of single-cell transcriptomics data from blood samples. Potential candidate drugs were predicted using the DrugBank database. Results We identified and preliminarily validated the expression levels of F2R Like Trypsin Receptor 1 (F2RL1) and Granzyme H (GZMH) in maternal blood samples from preeclampsia through quantitative experiments. Gene Set Enrichment Analysis (GSEA) indicated that F2RL1 is involved in the regulation of classical signaling pathways, including Toll-like receptor signaling pathway, pattern recognition receptor signaling pathway, oxidative stress-induced intrinsic apoptotic signaling pathway, and vesicle targeting processes. GZMH is primarily involved in immune processes associated with natural killer cells and also regulates lymphocyte chemotaxis. Analysis of single-cell sequencing datasets revealed significant changes in T cells and hematopoietic Stem Cell Growth Factor (HSC G-CSF) in the maternal blood system during the pathogenesis of preeclampsia. Receptor-ligand analysis and protein-drug analysis highlighted the important role of aspirin in the treatment of preeclampsia, as well as the potential value of tyrosine kinase inhibitors in preeclampsia treatment. Conclusion: This study identified the preeclampsia biomarkers F2RL1 and GZMH, which showed good diagnostic value, and predicted their potential biological functions. The disrupted immune environment in the maternal blood system and potential therapeutic drugs were explored through single-cell transcriptomics data analysis. This research provides new insights for the prediction of preeclampsia and deepens our understanding of the changes in the maternal blood system's immune environment during preeclampsia. However, further laboratory work and multicenter clinical evidence are still needed to clarify the clinical prospects of these findings.

Immunological Profiling of CD8+ and CD8- NK Cell Subpopulations and Immune Checkpoint Alterations in Early-Onset Preeclampsia and Healthy Pregnancy

Changes in expression levels of immune cells and inflammatory cytokines in pre-eclampsia patients before and after delivery

Placental Imbalance of Th1‐ and Th2‐type Cytokines in Preeclampsia

Mechanisms of Key Innate Immune Cells in Early- and Late-Onset Preeclampsia

Involvement of the PD-1/PD-L1 Co-Inhibitory Pathway in the Pathogenesis of the Inflammatory Stage of Early-Onset Preeclampsia

Integration of Single-Cell Sequencing and Transcriptomic Analysis to Identify Novel Diagnostic Biomarkers for Preeclampsia and Explore Changes in Immune Cell Interactions

Elevated Serum Levels of Interleukin-15 and Interleukin-16 in Preeclampsia.

Exploration of the molecular characteristics and potential clinical significance of shared immune-related genes between preterm preeclampsia and term preeclampsia

Imbalance of Serum T Helper 1- and 2-Type Cytokines in Preeclampsia and Gestational Hypertension

Single-cell profiling reveals immune disturbances landscape and HLA-F-mediated immune tolerance at the maternal-fetal interface in preeclampsia

Serum and Placental Interleukin-18 Are Elevated in Preeclampsia

Changes in the Ratio of Tc1/Tc2 and Th1/Th2 Cells but Not in Subtypes of NK-Cells in Preeclampsia

Preliminary study on the role of human defensins, interleukins and PCSK9 in early and late preeclampsia

The central role of natural killer cells in preeclampsia

Predictive biomarkers and initial analysis of maternal immune alterations in postpartum preeclampsia reveal an immune-driven pathology

Immunophenotypic Characteristics of Uterine Natural Killer Cells and Helper T Cell 1/ Helper T Cell 2 Immunity in the Third Trimester Decidua of Preeclampsia Patients

Maternal plasma proteome profiling of biomarkers and pathogenic mechanisms of early-onset and late-onset preeclampsia

Immunologic aspects of preeclampsia

CD158a+ /cd158b+ NK Cell Imbalance Correlates with Hypertension in Patients with Pre-Eclampsia.

Immune Imbalance is Associated with the Development of Preeclampsia

Circulating Immune Cells from Early- and Late-onset Pre-eclampsia Displays Distinct Profiles with Differential Impact on Endothelial Activation